Eloxx Pharmaceuticals Inc (NASDAQ: ELOX) is a clinical-stage biopharmaceutical company focused on developing drug candidates. The company has generated no product revenue as of the filings reviewed and funds operations through debt financing and equity issuances, including proceeds from pre-funded warrants. For the year ended December 31, 2025, financing activities provided $11.0 million in cash, consisting primarily of $9.7 million net proceeds from pre-funded warrants and $2.9 million from debt financing, partially offset by $1.3 million in term loan repayments. The company reported material weaknesses in internal controls over financial reporting as of December 31, 2025, citing inconsistent execution of financial close and reconciliation processes across fiscal years 2023, 2024, and 2025. Operations span multiple geographies and are subject to data protection regimes including the EU GDPR and U.S. state privacy laws.

Revenue model

No product revenue is supported by the filing excerpts. Operations are funded through equity issuances, pre-funded warrant sales, and debt financing. Collaboration partner advances have also contributed small amounts to financing cash flows.

Products and services

The filing excerpts reference product candidates in development but do not name specific drugs or clinical programs with sufficient detail to describe them here.

Customers and end markets

No customer names, customer counts, or end market revenue breakdowns are supported by the filing excerpts.

Value-chain role

Clinical-stage drug developer operating upstream of commercialization, conducting clinical trials and research across multiple geographies without approved or marketed products as supported by the filing excerpts.

Geographic exposure

Operations span multiple geographies including the United States and international jurisdictions. The company is subject to EU GDPR, UK data protection law, and U.S. federal and state privacy regulations, indicating presence in both the U.S. and Europe.

Source: SEC 10-K, filed 2026-03-17

Industry: Biological Products, (No Diagnostic Substances) Peers: Ampio Pharmaceuticals, Inc. TREX WIND-DOWN, INC. Avenir Wellness Solutions, Inc. PLx Pharma Winddown Corp. Evofem Biosciences Inc Johnson & Johnson KALA BIO Inc OTONOMY, INC. TITAN PHARMACEUTICALS INC